Investments in Unconsolidated Entities (Tables)

12 Months Ended

Dec. 31, 2021

Neuro Partners LLC and CGK [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the aggregation of summarized combined financial information of NeuroPartners LLC and CGK:

Neuro Partners LLC and CGK Combined Condensed Income Statement Information

	Years Ended December 31,
	2021			2020
Patient revenue	$	606,000		$	1,141,000
Net (loss) income	$	(9,000	)	$	391,000
USNC’s equity in (loss) income of Neuro Partners LLC and CGK	$	(36,000	)	$	124,000

Neuro Partners LLC and CGK Combined Condensed Balance Sheet Information

	December 31,
	2021		2020
Current assets	$	299,000	$	121,000
Noncurrent assets		294,000		551,000
Total assets	$	593,000	$	672,000
Current liabilities	$	564,000	$	634,000
Noncurrent liabilities		-		-
Equity		29,000		38,000
Total liabilities and equity	$	593,000	$	672,000

Boca Oncology Partners RE, LLC ("BOPRE") [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following tables present the summarized financial information of BOPRE:

BOPRE Condensed Income Statement Information

	Years Ended December 31,
	2021		2020
Rental Income	$	-	$	-
Net income	$	85,000	$	63,000
USNC’s equity in income in BOPRE	$	17,000	$	13,000

BOPRE Condensed Balance Sheet Information

	December 31,
	2021		2020
Current assets	$	112,000	$	27,000
Noncurrent assets		757,000		757,000
Total assets	$	869,000	$	784,000
Current liabilities	$	-	$	-
Noncurrent liabilities		-		-
Equity		869,000		784,000
Total liabilities and equity	$	869,000	$	784,000

Medical Oncology Partners LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following table presents the summarized financial information of MOP:

MOP Condensed Consolidated Income Statement Information

	Years Ended December 31,
	2021			2020
Patient revenue	$	2,417,000		$	2,104,000
Net loss	$	(646,000	)	$	(1,256,000	)
USNC’s equity in loss in MOP	$	(231,000	)	$	(450,000	)

MOP Condensed Consolidated Balance Sheet Information

	December 31,
	2021			2020
Current assets	$	201,000		$	204,000
Noncurrent assets		384,000			701,000
Total assets	$	585,000		$	905,000
Current liabilities	$	3,109,000		$	2,736,000
Noncurrent liabilities		92,000			410,000
Deficit		(2,616,000	)		(2,241,000	)
Total liabilities and deficit	$	585,000		$	905,000

CB Oncology Partners LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity Method Investment Summarized Financial Information

The following table presents the summarized financial information of CBOP:

CBOP Condensed Income Statement Information

	Years Ended December 31,
	2021			2020
Patient revenue	$	2,042,000		$	1,795,000
Net loss	$	(319,000	)	$	(730,000	)
USNC’s equity in loss  of CBOP	$	(91,000	)	$	(195,000	)

CBOP Condensed Balance Sheet Information

	December 31,
	2021			2020
Current assets	$	400,000		$	385,000
Noncurrent assets		3,667,000			4,271,000
Total assets	$	4,067,000		$	4,656,000
Current liabilities	$	3,472,000		$	3,181,000
Noncurrent liabilities		3,121,000			3,684,000
Deficit		(2,526,000	)		(2,209,000	)
Total liabilities and deficit	$	4,067,000		$	4,656,000